...said the treatment showed a positive trend toward remission rates vs. placebo.Sensei’s underwriters are Citigroup, Piper Sandler...

...iTeos’ are J.P. Morgan, SVB Leerink, Piper Sandler and Wedbush PacGrow. Inozyme’s are BofA Securities, Cowen, Piper Sandler...

...a temporary intraday halt during the day ahead of NASDAQ trading. Poseida’s were BofA Securities, Piper Sandler...

...bioVenture Partners, Sofinnova Investments, RA Capital, Novartis Bioventures and Fidelity. Underwriters are BofA Securities, Cowen, Piper Sandler...

...The deal valued Repare at $701.2 million. Underwriters are Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler...
...of its $14-$16 range, raising $100 million for a valuation of $677.5 million. Underwriters are Piper Sandler...

...Investors, Fidelity, EcoR1 Capital, Hatteras Venture Partners, Avidity Partners, Partner Fund Management, Emerson Collective and Piper Sandler...

...Lantern Pharma Inc. and Applied Molecular Transport Inc. (see “IPO Queue Grows” ). Citigroup, Cowen, Piper Sandler...
...Pliant’s deal. Targets CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper Sandler Needham Integrin...

...now part of AbbVie Inc. (NYSE:ABBV), following its acquisition of Tobira Therapeutics Inc. Citigroup, Cowen, Piper Sandler...

...a board seat, while OrbiMed has 8.5% (see “Arkin Ramping Up” ). Jefferies, SVB Leerink, Piper Sandler...